Welcome to our dedicated page for Skinhealth Systems news (Ticker: SKIN), a resource for investors and traders seeking the latest updates and insights on Skinhealth Systems stock.
The Beauty Health Company (NASDAQ: SKIN) generates a steady flow of news at the intersection of medical technology, professional aesthetics, and beauty. As the parent of Hydrafacial, SkinStylus, and Keravive, the company issues regular updates on financial performance, science-backed innovation, provider partnerships, and corporate governance, giving investors and industry followers insight into how its skin health platform is evolving.
On this page, readers can follow earnings announcements and financial results, where BeautyHealth reports net sales, gross margin, adjusted EBITDA, delivery systems sold, and active install base across the Americas, Asia-Pacific, and EMEA. These releases often include management commentary on trends in device sales versus consumables, the performance of the recurring revenue stream, and changes in regional go-to-market strategies.
News coverage also highlights product and innovation updates, such as the launch of boosters like HydraFillic with Pep9 and references to Hydralock HA Booster, as well as insights from the company’s Skintuition Report, which explores consumer trends in modern skin health and aesthetics. Additional stories focus on initiatives like the Hydrafacial Advisory Councils and Ambassador Network, which bring together plastic surgeons, dermatologists, aesthetic practitioners, and estheticians to guide product development, education, and clinical research.
Corporate and governance news includes executive appointments, board changes, and capital structure developments, such as the appointment of a new President and Chief Executive Officer, the addition of a new independent director, and updates related to convertible senior notes and charter amendments. For anyone tracking SKIN, this news feed offers a centralized view of the company’s operational progress, strategic priorities, and role in professional skin and scalp health.
SkinHealth Systems (NASDAQ: SKIN) will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. The company will host an investor conference call at 4:30 p.m. ET following a press release with results.
A live webcast and supporting materials will be available in the investor relations section of the company website at www.skinhealthsystems.com. A recording will be posted about three hours after the call concludes. The company uses SEC filings, press releases and public calls to disclose material information.
SkinHealth Systems (Nasdaq: SKIN) appointed three independent directors—Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie—effective April 17, 2026.
Each appointee brings sector expertise: medtech operations (Tripp), clinical aesthetics and trial experience (Shridharani), and global consumer brand leadership (Beattie). The Board currently totals 11 members and is expected to be nine after the 2026 Annual Meeting.
SkinHealth Systems (NASDAQ: SKIN) is the new corporate name for The Beauty Health Company, effective immediately with Nasdaq reflecting the change on April 23, 2026.
The rebrand signals a shift to a clinically driven, science-backed medical aesthetics platform while retaining Hydrafacial as its flagship and continuing to trade under the ticker SKIN.
The company emphasizes a device-plus-consumables model, a focus on device utilization, and a global installed base of more than 36,000 devices.
BeautyHealth (NASDAQ: SKIN) reported full year and Q4 2025 results with improved profitability and tighter costs despite lower equipment sales. 2025 net sales were $300.8M vs $334.3M in 2024; gross margin rose to 65.3% from 54.5% and adjusted EBITDA improved to $45.1M from $12.3M.
The company placed 3,726 delivery systems in 2025 (down from 4,907) and ended the year with ~$233M cash after repurchasing convertible notes; 2026 guidance targets $285–$305M net sales and $35–$45M adjusted EBITDA.
BeautyHealth (NASDAQ: SKIN) announced expanding adoption of its Hydrafacial and SkinStylus Nano-Channeling combination protocol across U.S. aesthetic and wellness providers, citing rising demand for combination treatments that deliver enhanced results with no downtime. The company highlighted provider adoption, a LifeSpa rollout, and survey data showing broad consumer and provider support for combination therapies.
BeautyHealth (NASDAQ:SKIN) will report Q4 and full-year 2025 financial results after market close on March 12, 2026.
The company will host an investor conference call at 4:30 p.m. ET the same day with a live webcast and supporting materials on https://investors.beautyhealth.com. A recording will be available about three hours after the call concludes.
BeautyHealth (NASDAQ: SKIN) released Skintuition Report: Volume Three on December 4, 2025, profiling consumer shifts toward skin regeneration over correction.
Key metrics: 75% of consumers now prioritize treatments that improve overall skin quality; Hydrafacial reports an average of 3.6 treatments per year per client and 50% of clients purchase an add-on treatment or retail product during visits. The company highlights the June 2025 launch of the HydraFillic with Pep9 Booster and cites a clinical study showing measurable improvements 24 hours after treatment in 30 participants.
BeautyHealth (NASDAQ: SKIN) reported Q3 2025 results for the quarter ended September 30, 2025. Net sales were $70.7M, down (10.3)% year‑over‑year. Gross margin improved to 64.6% from 51.6% a year ago, and adjusted gross margin was 68.0%. Net loss narrowed to $(11.0)M and Adjusted EBITDA rose to $8.9M from $8.1M. The company placed 875 delivery systems (vs. 1,118 prior year) and reported an active install base of 35,409. Cash and equivalents were approximately $219M as of September 30, 2025. Fiscal 2025 guidance was updated to $293–$300M net sales and $37–$39M adjusted EBITDA.
BeautyHealth (NASDAQ: SKIN) appointed Philippe Schaison, PharmaD to its Board of Directors, effective October 30, 2025. Schaison brings over 20 years of leadership across global aesthetics, biotech, and consumer health, including roles as CEO NA of Syneron Candela and President of Allergan Aesthetics, and current CEO of Soltégo, Inc.
He will join the Compensation and Nominating & Corporate Governance Committees. Following the appointment, the Board will total eight directors. The company said Schaison’s experience should help expand Hydrafacial’s global reach and accelerate category growth.
Beauty Health (NASDAQ:SKIN) will report third quarter 2025 financial results after market close on Thursday, November 6, 2025. The company will host an investor conference call at 4:30 p.m. Eastern Time following a press release that details the results.
A live webcast and supporting materials will be available on the company investor relations website at https://investors.beautyhealth.com. A recording of the call will be posted approximately three hours after the call concludes. The company discloses material information via SEC filings, press releases, public calls, and its investor relations website to comply with Regulation FD.